^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NMS-P118

    i
    Other names: NMS-P118
    Associations

    News

    Trials
    Company:
    Nerviano Medical Sciences
    Drug class:
    PARP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    [VIRTUAL] Structure-based and property-based drug design of AZD5305, a highly selective PARP1 inhibitor and trapper (AACR 2021)
    Since the approval of olaparib in 2014 for BRCA mutated (BRCAm) ovarian cancer, many PARP inhibitors have been developed and have seen widespread success...The publication of NMS-P118 in 2015 by Nerviano Medical Sciences showed that a highly selective PARP1 inhibitor could be found...The secondary pharmacology of AZD5305 is remarkably clean, with hERG activity >40 µM. AZD5305 has a very favorable pre-clinical PK profile, low predicted human dose, and has shown efficacy in an MDA-MB-436 mouse xenograft model.
    BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • saruparib (AZD5305) • NMS-P118